On emerging enzyme replacement therapies for neuronopathic mucopolysaccharidosis II

Mol Genet Metab. 2024 Mar;141(3):108143. doi: 10.1016/j.ymgme.2024.108143. Epub 2024 Jan 14.

Authors

Y Sato¹, P Yoshida², T Yamamoto², S So², K Tanizawa²

Affiliations

¹ JCR Pharmaceuticals, Hyogo, Japan. Electronic address: sato-yuji@jp.jcrpharm.com.
² JCR Pharmaceuticals, Hyogo, Japan.

PMID: 38277987
DOI: 10.1016/j.ymgme.2024.108143

No abstract available

Publication types

Letter

MeSH terms

Enzyme Replacement Therapy
Humans
Mucopolysaccharidosis II* / drug therapy